Clinical Trials on Oligometastatic Esophageal Adenocarcinoma in China

Total 2706 results

ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastric Adenocarcinoma | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8 | Clinical... and other conditions

United States
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Oligometastatic Disease | Immunotherapy | Esophagus Cancer | Chemoradiotherapy

China
Fudan University

Active, not recruiting

Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Henan University...

Unknown

Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer

Stage III Esophageal Squamous Cell Carcinoma | Stage II Esophageal Squamous Cell Carcinoma | Stage I Esophageal Adenocarcinoma | Stage II Esophageal Adenocarcinoma | Stage III Esophageal Adenocarcinoma | Stage I Esophageal Squamous Cell Carcinoma

China
Fudan University

Recruiting

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease | Radiotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC (LEO)

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China
Ruihua Xu

Recruiting

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Friendship Hospital; Chinese PLA General Hospital; Beijing Hospital

Recruiting

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma

China
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Curegenix Inc.
Guangzhou Curegenix Co. Ltd.

Unknown

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastrointestinal Cancer | Esophageal Carcinoma | Colorectal Adenocarcinoma | Bile Duct Carcinoma

China
Peking University
Gracell Biopharmaceuticals, Inc.

Recruiting

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Astellas Pharma China, Inc.

Completed

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

China
Fudan University

Recruiting

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

Gastric / Gastroesophageal Junction Adenocarcinoma

China
Fudan University

Enrolling by invitation

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin

Gastric / Gastroesophageal Junction Adenocarcinoma

China
Sun Yat-sen University
Affiliated Cancer Hospital of Shantou University Medical College

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Esophageal Cancer | Oesophageal Cancer | Squamous Cell Esophageal Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma (Siewert II-III)

China
Sun Yat-sen University

Recruiting

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Akeso

Recruiting

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Active, not recruiting

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Gastric Adenocarcinoma | Advanced Solid Tumors | Gastroesophageal Junction Adenocarcinoma

China
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

China
Guangdong Provincial Hospital of Traditional Chinese...

Recruiting

A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG

Siewert Type II Adenocarcinoma of Esophagogastric Junction | Esophagogastric Junction Adenocarcinoma

China
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
China Medical University, China

Recruiting

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma | AFP

China
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
The First Affiliated Hospital of Xiamen University

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

China
Xijing Hospital of Digestive Diseases
First Affiliated Hospital Xi'an Jiaotong University; Henan Provincial People... and other collaborators

Recruiting

Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

Siewert Type II Adenocarcinoma of Esophagogastric Junction

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Sixth Affiliated Hospital, Sun Yat-sen University
Sun Yat-sen University

Recruiting

S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma

Chemotherapy Effect | Locally Advanced Gastroesophageal Junction Adenocarcinoma

China
Changhai Hospital
Stemirna Therapeutics

Unknown

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Colorectal Adenocarcinoma | Advanced Esophageal Squamous Carcinoma

China
Pfizer

Terminated

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Gastrointestinal Tumors | Esophageal Adenocarcinomas | Colorectal Adenocarcinomas | Gastric Adenocarcinomas

United States, Australia, Japan
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Terminated

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

Oesophageal Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Chinese PLA General Hospital

Recruiting

Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction

Adenocarcinoma of Esophagogastric Junction

China
Fudan University

Unknown

Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction (GCQOL01)

Adenocarcinoma of Esophagogastric Junction.

China
Hebei Medical University

Completed

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction (A-C)

Gastroesophageal Junction Adenocarcinoma

China
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Qilu Hospital of Shandong University

Recruiting

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Hebei Medical University

Unknown

Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

Gastroesophageal Junction Adenocarcinoma

China
Peking University
Peking University People's Hospital; Beijing Friendship Hospital; Chinese PLA...

Unknown

Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma (KEYSTONE-003)

Pembrolizumab | Neoadjuvant Chemotherapy | Adenocarcinoma of Esophagogastric Junction

China
Fujian Cancer Hospital

Unknown

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China

Clinical Trials on Oligometastatic Esophageal Adenocarcinoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations